BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025)
BridgeBio Pharma (BBIO) posted Tax Provisions of -$165000.0 for Q4 2025, up 89.32% sequentially from -$1.5 million in Q3 2025, and down 114.31% YoY from $1.2 million in Q4 2024.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025) Analysis & Trends
BridgeBio Pharma has reported Tax Provisions for 2 years, with the latest figure at -$165000.0 in Q4 2025.
- Quarterly Tax Provisions fell 114.31% year-over-year to -$165000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $435000.0, down 62.27% from the prior year.
- Tax Provisions rose to -$165000.0 in Q4 2025 per BBIO's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Tax Provisions peaked at $2.1 million in Q2 2025 and troughed at -$1.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -165,000.00 |
| Sep 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Dec 31, 2024 | 1.15 Mn |